-
公开(公告)号:US20060287295A1
公开(公告)日:2006-12-21
申请号:US10572794
申请日:2004-09-22
IPC分类号: A61K31/553 , A61K31/551 , A61K31/541 , A61K31/5377 , A61K31/517 , C07D417/02 , C07D413/02 , C07D403/02
CPC分类号: C07D413/14 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14
摘要: The invention concerns quinazoline derivatives of Formula (I), wherein each of R1a, R1b, R2, R3 and a have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
摘要翻译: 本发明涉及式(I)的喹唑啉衍生物,其中R 1a,R 1b,R 2,R 3, / SUP>和a具有描述中定义的任何含义; 其制备方法,含有它们的药物组合物及其在制备用于预防或治疗对erbB受体酪氨酸激酶抑制敏感的肿瘤中的抗增殖剂的药物中的用途。
-
公开(公告)号:US20070043010A1
公开(公告)日:2007-02-22
申请号:US10573352
申请日:2004-09-22
IPC分类号: A61K31/33
CPC分类号: C07D403/12 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14
摘要: The invention concerns a quinazoline derivative of the Formula (I): wherein each of the variables have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
摘要翻译: 本发明涉及式(I)的喹唑啉衍生物:其中每个变量具有说明书中定义的任何含义; 其制备方法,含有它们的药物组合物及其在制备用于预防或治疗对erbB受体酪氨酸激酶抑制敏感的肿瘤中的抗增殖剂的药物中的用途。
-
公开(公告)号:US20070032513A1
公开(公告)日:2007-02-08
申请号:US10572261
申请日:2004-09-13
IPC分类号: A61K31/517 , C07D403/02
CPC分类号: C07D403/12 , C07D401/12 , C07D403/14
摘要: The invention concerns quinazoline derivatives of the Formula I: (A chemical formula should be inserted here—please see paper copy enclosed herewith) wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.
摘要翻译: 本发明涉及式I的喹唑啉衍生物:(化学式应在此插入,请参见随附的纸质复制品),其中R 1,R 2,W,X 1,X 2,Z,a和b各自如说明书中所定义 ; 其准备过程; 含有它们的药物组合物及其在制备用于提供抗增殖作用的药物中的用途。 预期式I的喹唑啉衍生物可用于治疗疾病,例如由erbB受体酪氨酸激酶,特别是EGFR酪氨酸激酶介导的某些癌症。
-
公开(公告)号:US20070293490A1
公开(公告)日:2007-12-20
申请号:US10586965
申请日:2005-01-31
申请人: Benedicte Delouvrie , Craig Harris , Laurent Hennequin , Christopher Halsall , Janet Pease , Peter Smith
发明人: Benedicte Delouvrie , Craig Harris , Laurent Hennequin , Christopher Halsall , Janet Pease , Peter Smith
IPC分类号: A61K31/517 , A61K31/5377 , A61P35/00 , C07D239/94 , C07D413/12
CPC分类号: C07D239/42 , C07D401/12 , C07D403/12
摘要: A quinazoline derivative of the formula (I) wherein: R1, R2, R3, R3a, R4, R5, R5a R6, R7, a, m and p are as defined in the description. Also claimed are pharmaceutical compositions containing the quinazoline derivative, the use of the quinazoline derivatives as medicaments and processes for the preparation of the quinazoline derivative. The quinazoline derivatives of formula (I), are useful in the treatment of hyperproliferative disorders such as a cancer.
摘要翻译: 式(I)的喹唑啉衍生物其中:R 1,R 2,R 3,R 3, R 4,R 5,R 5,R 6,R 7,R 7, a,m和p如说明书中所定义。 还要求的是含有喹唑啉衍生物的药物组合物,喹唑啉衍生物作为药物的用途以及制备喹唑啉衍生物的方法。 式(I)的喹唑啉衍生物可用于治疗过度增殖性疾病如癌症。
-
公开(公告)号:US20070043009A1
公开(公告)日:2007-02-22
申请号:US10573090
申请日:2004-09-13
IPC分类号: A61K31/33
CPC分类号: C04B35/632 , C07D401/12 , C07D401/14 , C07D405/14
摘要: The invention concerns quinazoline derivatives of the Formula (I); wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula (I) are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.
摘要翻译: 本发明涉及式(I)的喹唑啉衍生物; 其中R 1,R 2,W,X 1,X 2,Z,a和b中的每一个 如说明书中所定义; 其准备过程; 含有它们的药物组合物及其在制备用于提供抗增殖作用的药物中的用途。 预期式(I)的喹唑啉衍生物可用于治疗诸如由erbB受体酪氨酸激酶,特别是EGFR酪氨酸激酶介导的某些癌症的疾病。
-
-
-
-